Impact of neoadjuvant chemotherapy in the surgical treatment of breast cancer
Authors:
- Marcelo AntoniniMAMarcelo Antonini
- André MattarAndré Mattar
- Gabriel Duque PannainGPGabriel Duque Pannain
- Odair FerraroOFOdair Ferraro
- Reginaldo Guedes Coelho LopesRLReginaldo Guedes Coelho Lopes
- Luiz Henrique GebrimLGLuiz Henrique Gebrim
- Juliana Monte RealJRJuliana Monte Real
- Maria Augusta Carvalho e SilvaMSMaria Augusta Carvalho e Silva
Open Access
Abstract
Introduction: Neoadjuvant chemotherapy is an increasingly frequent option in the treatment of breast cancer. One of the goals of neoadjuvant chemotherapy is to change the indication for a mastectomy to a conservative surgery, and for axillary lymphadenectomy to sentinel lymph node assessment. Methods: This was an observational, cross-sectional, retrospective study that evaluated response to neoadjuvant chemotherapy in breast cancer patients undergoing surgical treatment. Patients were divided into three groups when the surgery indication was changed after neoadjuvant chemotherapy: downgrade, unchanged, upgrade. Results: During the study period, 355 patients were included with a mean age of 55 years. Neoadjuvant chemotherapy promoted a downgrade in 38.7% of patients with indication for mastectomy and an upgrade in 36.8% of patients with indication for conservative surgery; in the total group, the maintenance of indication for surgery was 62,2%. In the axillary approach, lymphadenectomy downgrade was 6.9% and sentinel lymph node biopsy upgrade was 34% with 27% being due to positivity and 7% due to disease progression. Multivariate analysis found a significant difference between clinical staging and change in surgical indication for both breast and axilla (p<0.0001). In the multivariate analysis of pathologic complete response and change of indication for breast and axilla surgery, triple negative and HER-2-positive tumors showed a significant difference (p<0.0001). Conclusions: Neoadjuvant chemotherapy was able to perform a downgrade of breast and axilla surgery in few patients and there was no relationship between the change of indication and pathologic complete responseKeywords
This publication has 24 references indexed in Scilit:
- Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysisClinical Cancer Research, 2020
- Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A MicrosimulationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2019
- Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidenceThe Lancet, 2019
- PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trialsBreast Cancer Research and Treatment, 2018
- Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysisAnnals of Oncology, 2018
- Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a ReviewCurrent Treatment Options in Oncology, 2018
- Psychological impact of providing women with personalised 10-year breast cancer risk estimatesBritish Journal of Cancer, 2018
- S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients – Results of the GeparTrio Trial.Cancer Research, 2011
- International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010)JNCI Monographs, 2011